Compare ADMA Biologics Inc (ADMA) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Atlassian Corporation PLC — how do they compare? ADMA Biologics Inc trades at $9.2 (market cap $2.13B), while Atlassian Corporation PLC trades at $86.12 (market cap $22.43B). The key difference: Atlassian Corporation PLC is far larger — about 10.5× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | TEAM | |
|---|---|---|
Market Cap | $2.13B | $22.43B |
Sector | Health | Technology |
52-Week High | $20.38 | $220.89 |
52-Week Low | $7.60 | $57.15 |
Enterprise Value | $2.20B | $22.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Atlassian (TEAM) trades at $88.39, up 5.43% with bullish technical signals despite negative profitability metrics. The stock shows strong revenue growth from $2.8B in 2022 to $5.2B in 2025, though net losses persist. Recent earnings beats and cloud revenue momentum of 29% in Q3 FY26 support optimism. Analyst consensus is strongly bullish with 30 buy ratings and a $120.29 price target, representing 36% upside potential.
The outlook remains positive driven by enterprise adoption and AI integration, but investors face risks from persistent losses, high valuation multiples, and competitive pressures. With improving margins and strong institutional support, TEAM offers growth exposure but requires tolerance for current unprofitability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
